Radiation and first treatment for older adults with colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new way of giving radiation therapy in smaller, more frequent doses along with your first round of systemic treatment (chemo or other drugs) for metastatic colorectal cancer. The goal is to find a treatment that is effective and easier for older or frailer patients to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 or older, or you are 60–69 and need help with daily activities.
- Your colorectal cancer has spread to other organs (like the liver or lungs).
- You have at least one tumor that can be measured on scans.
- You have not had standard first-line chemotherapy for this cancer, or you finished chemo after surgery more than 6 months ago.
- You have not had immunotherapy before.
- You should have 10 or fewer cancer spots, and all of them are safe to treat with radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation therapy combined with medication for older or frail patients with colorectal cancer that cannot be removed by surgery. The goal is to control the cancer while reducing side effects and improving quality of life.
This trial studies a special type of radiation therapy for older adults with rectal cancer who are not able or willing to have surgery. It combines external beam radiation with a short, focused radiation treatment inside the rectum (brachytherapy) to try to control the cancer while avoiding the risks of surgery.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a new combination of short-course radiation, a targeted drug (fruquintinib), and an immunotherapy drug (PD-1 inhibitor) to treat rectal cancer before surgery. It aims to shrink the tumor and improve outcomes for patients with a specific type of rectal cancer.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a new type of radiation therapy that uses real-time MRI imaging to adjust the radiation precisely to your tumor. It is designed to improve the accuracy of treatment for locally advanced rectal cancer, potentially reducing damage to nearby healthy tissue.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.